ストックスクリーナーアプリを入手
33.12
13.23%
3.87
プレマーケット:
33.21
0.09
+0.27%
Mineralys Therapeutics Inc (MLYS) 最新ニュース
How to interpret RSI for Mineralys Therapeutics Inc. stock2025 Technical Patterns & Risk Managed Investment Signals - Newser
Chart overlay techniques for tracking Mineralys Therapeutics Inc.July 2025 Analyst Calls & AI Enhanced Trading Signals - Newser
Can volume confirm reversal in Mineralys Therapeutics Inc.Weekly Trend Report & Verified Technical Trade Signals - Newser
Mineralys Therapeutics Inc. stock trend forecastTrade Risk Assessment & AI Based Trade Execution Alerts - Newser
How moving averages guide Mineralys Therapeutics Inc. trading2025 Volume Leaders & Smart Allocation Stock Tips - Newser
Is Mineralys Therapeutics Inc. still worth holding after the dip2025 Technical Overview & Safe Entry Trade Signal Reports - Newser
Is Mineralys Therapeutics Inc.’s ROIC above industry average2025 Support & Resistance & Consistent Profit Trading Strategies - khodrobank.com
Analyzing Mineralys Therapeutics Inc. with risk reward ratio chartsNew Guidance & Free Technical Pattern Based Buy Signals - Newser
Mineralys Therapeutics Closes $287.5 Million Public Offering to Support Clinical Development of Lorundrostat - Quiver Quantitative
Mineralys Therapeutics closes $287.5 million public offering - Investing.com
Mineralys Therapeutics Announces Closing of Upsized $287.5 Million Underwritten Public Offering of Common Stock Including Full Exercise of Underwriters’ Option to Purchase Additional Shares - GlobeNewswire
$287.5M Raised: Hypertension Drug Developer Mineralys Completes Major Public Offering for Clinical Trials - Stock Titan
Can Mineralys Therapeutics Inc. disrupt its industryJuly 2025 Patterns & High Accuracy Swing Trade Signals - khodrobank.com
Using data tools to time your Mineralys Therapeutics Inc. exitJuly 2025 Volume & Free Technical Confirmation Trade Alerts - Newser
Jefferies expects Mineralys stock to trade up following AstraZeneca data - MSN
How sentiment analysis helps forecast Mineralys Therapeutics Inc.Quarterly Earnings Report & AI Based Buy/Sell Signal Reports - Newser
What high frequency data says about Mineralys Therapeutics Inc.July 2025 Highlights & Technical Entry and Exit Alerts - Newser
Mineralys surges after late-stage trial data AstraZeneca’s blood pressure drug - MSN
Advanced analytics toolkit walkthrough for Mineralys Therapeutics Inc.July 2025 Selloffs & Verified Trade Idea Suggestions - Newser
Will Mineralys Therapeutics Inc. benefit from AI trends2025 Analyst Calls & Technical Pattern Based Signals - khodrobank.com
Predicting Mineralys Therapeutics Inc. trend using moving averagesEarnings Miss & Real-Time Volume Analysis Alerts - Newser
Is Mineralys Therapeutics Inc. reversing from oversold territoryTreasury Yields & Weekly Hot Stock Watchlists - Newser
Live market analysis of Mineralys Therapeutics Inc.Earnings Overview Summary & Real-Time Chart Pattern Alerts - Newser
Order flow analysis tools used on Mineralys Therapeutics Inc.Entry Point & Expert Curated Trade Setup Alerts - Newser
Mineralys Therapeutics Announces Public Offering of Shares - TipRanks
Mineralys Therapeutics launches $175M public offering - MSN
Mineralys: Soaring As Rival's Hypertension Data Falls ShortBuy The Next Dip (MLYS) - Seeking Alpha
Stock Market Update: Bruker, Mineralys Therapeutics, and Other Big Stocks Moving Lower in Wednesday's Pre-Market Session - AInvest
Mineralys In The Money As Lorundrostat Gets Close To Market - insights.citeline.com
Mineralys (MLYS) Steals Spotlight From AstraZeneca, Reaches Fresh Peak - MSN
Mineralys’ strategic stock sale; Gilead, Shoreline partnership ends - Endpoints News
Mineralys Therapeutics prices upsized $250M stock offering - MSN
Short interest data insights for Mineralys Therapeutics Inc.July 2025 Gainers & Free Reliable Trade Execution Plans - Newser
Latham Advises Mineralys Therapeutics on Upsized US$250 Million Underwritten Public Offering of Common Stock - Latham & Watkins LLP
Institutional scanner results for Mineralys Therapeutics Inc.Portfolio Return Report & Long-Term Growth Plans - Newser
Bruker, Mineralys Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
Identifying reversal signals in Mineralys Therapeutics Inc.2025 Key Lessons & Safe Entry Trade Signal Reports - Newser
Jefferies raises Mineralys Therapeutics stock price target to $26 from $15 - Investing.com
Will Mineralys Therapeutics Inc. announce a stock splitPortfolio Gains Summary & Technical Pattern Recognition Alerts - khodrobank.com
Mineralys Therapeutics shares fall 6.38% premarket after suspending prospectus supplement for ATM equity offering. - AInvest
Q&A with Jon Congleton, CEO of Mineralys Therapeutics - The Pharma Letter
Mineralys Therapeutics Prices $250 Million Notes Offering - MarketScreener
Mineralys Therapeutics stock hits all-time high at 22.0 USD By Investing.com - Investing.com Canada
What MACD and RSI say about Mineralys Therapeutics Inc.Earnings Overview Summary & Weekly Watchlist for Consistent Profits - Newser
Published on: 2025-09-03 02:21:26 - Newser
Key metrics from Mineralys Therapeutics Inc.’s quarterly dataJuly 2025 Drop Watch & Stepwise Trade Execution Plans - Newser
Using RSI to spot recovery in Mineralys Therapeutics Inc.July 2025 Patterns & Technical Confirmation Trade Alerts - Newser
Mineralys Therapeutics' $250M Upsized Equity Raise: A Strategic Inflection Point for Hypertension Innovation - AInvest
Published on: 2025-09-03 00:47:22 - Newser
Published on: 2025-09-03 00:45:39 - Newser
$250 Million Stock Offering: Hypertension Drug Developer Mineralys Prices Upsized Public Share Sale - Stock Titan
Mineralys Therapeutics Prices Upsized Public Offering Of 9.80 Mln At $25.50/shr - Nasdaq
Mineralys Therapeutics Announces Upsized Public Offering of Common Stock Raising Approximately $250 Million - Quiver Quantitative
1.75%
1.11%
大文字化:
|
ボリューム (24 時間):